A combination of 2-acetoxy-5-(Î±-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.

Claims

5 · 1 independent · depth 3

5 granted claims

›1.independentA pharmaceutical composition consisting essentially of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a…+4

Classifications

5 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/4743
A61K31/60

USPC · US Patent Classification

514/301514/161514/165

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

4.9 y

1,789 days filing → grant

Office actions

non-final + final

Responses

7 RCE

Interviews

examiner interview summaries

Examiner

Brian Kwon

art unit 1614 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 22 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20040024013 A1	5 Feb 2004

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.